Aerosol delivery devices Market Increase In Analysis and Development Activities Is More Boosting Demands

Comments · 30 Views

Aerosol drug devices can treat a host of diseases such as lung diseases, pneumonia, diabetes, asthma, etc. which further drives the global aerosol delivery devices market during the forecast years.

The global Aerosol delivery devices Market is foreseen to expand at a CAGR of 4.9% and reach the valuation of USD 46.72bn in 2027 in comparison to USD 31.46bn in 2019.

Aerosol drug devices can treat a host of diseases such as lung diseases, pneumonia, diabetes, asthma, etc. which further drives the global aerosol delivery devices market during the forecast years.

Researchmoz elucidates the market in detail including market size, opportunities, restraints, drivers, and segment domination.

Chronic obstructive pulmonary disease (COPD) to Drive the Market

Chronic obstructive pulmonary disease (COPD) is the most common death-causing disease in the world and drug delivery via inhalation process is the common treatment for COPD. The disease affects nearly 15% of the US population, thus, the increasing prevalence of COPD is projected to drive the global aerosol delivery devices market.

 

The drug delivery system has had a transformational shift since its inception, from just metered-dose inhalers to handheld inhalers such as dry powder and soft mist inhalers. The growing patient population and growing need for targeted therapies have encouraged a better understanding of the applications of aerosol drug delivery.

Self-administration to Boost the Sales of Aerosol Delivery Devices

The pharmaceutical industry is highly focused on patient-centricity through bringing in self-administration and giving ease and real-time experiences to the patients, owing to the expansion of the global aerosol delivery devices market.

According to pharma experts, innovations in the field of drug delivery will make manufacturers and pharma companies, researchers, and scientists to work together and introduce digitization, leading to the expansion of the global aerosol delivery devices market.

The high cost of treatment and side effects of medication might hinder the growth of the global aerosol delivery devices market to some extent.

However, the rising geriatric population with severe respiratory diseases such as asthma, COPD, etc. will drive the global aerosol delivery devices market.

Request A Sample: https://www.researchmoz.us/request-free-sample/?reportid=531

Some of the prominent players in the global aerosol drug delivery market are-

  • Koninklijke Philips N.V.
  • 3M Company
  • Aerogen, INC
  • GlaxoSmithKline Plc (GSK)
  • Merck co., INC.
  • Metall Zug Group (Clement Clarke International Ltd)
  • Merxin LTD
  • Nemera
  • Iconovo AB
  • Gerresheimer AG
  • Recipharm AB (Bespak)
  • Johnson Johnson (Actelion Pharmaceuticals Ltd)
  • Teva Pharmaceutical Industries Limited
  • Vectura Group PLC

Product Outlook

  • Dry powder inhalers
    • Single-dose inhalers
    • Multi-dose inhalers
    • Reservoir Inhalers
  • Metered-dose inhalers
    • Conventional pressurized inhalers,
    • Soft mist inhalers
  • Nebulizers
    • Jet nebulizers
    • Ultrasonic wave nebulizers
    • Vibrating mesh nebulizers

Application Outlook

  • Asthma
  • Chronic obstructive pulmonary disease
  • Cystic fibrosis

Non-respiratory diseases

  • Diabetes
  • Analgesia
  • Parkinson’s disease
Comments